Atria Investments’s BridgeBio Pharma BBIO Stock Holding History

Atria Investments’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$201K	Buy	+3,058	New	+$238K	﹤0.01%	2075

Other funds holding BBIO

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

Burney Company Reston, Virginia $3.66B AUM 27.59% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

CPBTD

Central Pacific Bank - Trust Division Honolulu, Hawaii $952M AUM 25.15% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Atria Investments's BBIO Position: Q3 2026 in Review

Atria Investments opened a new position in BridgeBio Pharma (BBIO) in Q3 2026: 3,058 shares worth $201K. The stake represents ﹤0.01% of the portfolio and ranks #2075 among its holdings.

38 funds tracked by Wall St. Rank hold BBIO as of Q3 2026.

Atria Investments held 3,058 shares of BridgeBio Pharma worth $201K as of Q3 2026.
BridgeBio Pharma was a new Atria Investments position in Q3 2026.
BridgeBio Pharma made up ﹤0.01% of Atria Investments's portfolio in Q3 2026, its #2075 holding.
38 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2026.

Based on Atria Investments's 13F filing for Q3 2026, filed 15 Oct 2026.